Logo

Invitrogen s Earnings, Sales Soar in Q4

Feb 12, 2004

NEW YORK, Feb. 12 (GenomeWeb News) - Invitrogen reported increased earnings and revenues for the fourth quarter today.

 

Revenues increased to $207.8 million, from $161.8 million during the same period the previous year. Invitrogen attributed this increase in sales mainly to products it obtained from its acquisitions of Molecular Probes, Pan Vera, and InforMax.

 

R&D expenses soared to $16.1 million, from $9.7 million during the same quarter in 2002.

 

Net income for the quarter was $12.6 million, or $.24 per share, up from $10.2 million, or $.2 per share, the year before.

 

As of Dec. 31, 2003, Invitrogen had $998.7 million in cash and investments.

 

 

Breaking News
The Scan

Gone, But Now Reconstructed SARS-CoV-2 Genomes

In a preprint, a researcher describes his recovery of viral sequences that had been removed from a common database.

Rare Heart Inflammation Warning

The Food and Drug Administration is adding a warning about links between a rare inflammatory heart condition and two SARS-CoV-2 vaccines, Reuters reports.

Sandwich Sampling

The New York Times sent tuna sandwiches for PCR analysis.

Nature Papers Describe Gut Viruses, New Format for Storing Quantitative Genomic Data, More

In Nature this week: catalog of DNA viruses of the human gut microbiome, new dense depth data dump format to store quantitative genomic data, and more.